At week 78 , the between-group differences in the change from baseline in the ADAS-cog11 and DAD scores ( bapineuzumab group minus placebo group ) were -0.2 ( P = 0.80 ) and -1.2 ( P = 0.34 ) , respectively , in the carrier study ; the corresponding differences in the noncarrier study were -0.3 ( P = 0.64 ) and 2.8 ( P = 0.07 ) with the 0.5-mg-per-kilogram dose of bapineuzumab and 0.4 ( P = 0.62 ) and 0.9 ( P = 0.55 ) with the 1.0-mg-per-kilogram dose .